Metipranolol overdosage: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Metipranolol}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METIPRANOLOL SOLUTION/ DROPS [FALCON PHARMACEUTICALS, LTD...." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Overdosage== | ||
No information is available on overdosage of metipranolol ophthalmic solution in humans. The symptoms which might be expected with an overdose of a systemically administered beta-adrenergic receptor blocking agent are bradycardia, hypotension and acute cardiac failure.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METIPRANOLOL SOLUTION/ DROPS [FALCON PHARMACEUTICALS, LTD.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=699ce415-0798-4244-b5ec-bcdb383b50b3#nlm34090-1 | publisher = | date = | accessdate = }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METIPRANOLOL SOLUTION/ DROPS [FALCON PHARMACEUTICALS, LTD.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=699ce415-0798-4244-b5ec-bcdb383b50b3#nlm34090-1 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 05:23, 10 February 2014
| Metipranolol |
|---|
| METIPRANOLOL® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Metipranolol |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overdosage
No information is available on overdosage of metipranolol ophthalmic solution in humans. The symptoms which might be expected with an overdose of a systemically administered beta-adrenergic receptor blocking agent are bradycardia, hypotension and acute cardiac failure.[1]
References
Adapted from the FDA Package Insert.